PubMed · 2014 · 92 citations · 21 references
MedicineImmunologyOncologyCancer ImmunologyImmunoregulationTumor ProgressionCytokines In Tumor ImmunityCytotoxic T Lymphocyte ResponsesImmuno-oncology BiomarkersMyeloid-derived Suppressor CellsT Cell Responses To TumorsTumor ImmunopathologyMyeloid-derived Suppressor Cell BiomarkersMyeloid-derived Suppressor Cell Clinical SignificanceMyeloid-derived Suppressor Cell CytokinesMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell MarkersMyeloid-derived Suppressor Cell PhenotypeMyeloid-derived Suppressor Cell-mediated SuppressionT Cell Response Induction
AIM: Myeloid-derived suppressor cells (MDSCs) are a population of cells which negatively regulate immune response during tumor progression. In this study, we assessed the accumulation of MDSCs (CD33(+)CD11b(+)HLA-DR(-)CD14(-)) in patients with prostate cancer and its clinical relevance. METHODS: We tested the frequency of MDSCs in the peripheral blood of patients with prostate cancer or benign prostate hyperplasia and healthy donors. Serumal interleukin-8, -6 and -10 were analyzed. Effects of MDSCs on the T cell response were determined. RESULTS: MDSCs increased in cancer patients, and there was an association between MDSCs and cancer stages or overall survival. Elevated serumal interleukin-8 and -6 in cancer patients correlated with MDSCs. Moreover, accumulation of MDSCs was associated with defective T cell function. CONCLUSION: Our study showed an increased population of MDSCs in patients with prostate cancer. Interleukin-8 and -6 in serum may play a new important role companied with MDSCs in prostate cancer.
21
C. Marcela Díaz‐Montero, Mohamed L. Salem, Michael I. Nishimura et al. · Cancer Immunology Immunotherapy · 2008 · 1.2K citations
Medicine, Cancer Biology, Oncology +17